Survey of treatment recommendations for anaplastic oligodendroglioma - Wikidata - awgldk - TriplyDB

Survey of treatment recommendations for anaplastic oligodendroglioma

Survey of treatment recommendations for anaplastic oligodendroglioma

http://www.wikidata.org/entity/Q30441461

about

Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors Initial treatment patterns over time for anaplastic oligodendroglial tumors.International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population Temozolomide in malignant glioma Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers The future of high-grade glioma: Where we are and where are we going.Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade.Insights into pharmacotherapy of malignant glioma in adults.Anaplastic oligodendroglioma.Loss of heterozygosity analysis in malignant gliomas.Diagnosis of oligodendroglioma: molecular and classical histological assessment in the twenty-first century.Diagnostic and prognostic markers in gliomas - an update.Anaplastic glioma: current treatment and management.Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.Anaplastic oligodendroglioma: advances and treatment options.Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients.A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12.Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.Moving toward molecular classification of diffuse gliomas in adults.Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.Response to Weltman and Fleury Malheiros, re Lassman et al.Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.Success at last: a molecular factor that informs treatment.Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.Current therapeutic approaches to diffuse grade II and III gliomas.Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe.Prognostic factors and outcomes in anaplastic gliomas: An institutional experience.High-grade gliomas.

P2860

Q26853516-8A482C8E-690C-47ED-85AB-8ECCCB7BD252 Q30370204-576FC737-9231-41BC-A010-8CAD3BBAF7D8 Q30419123-234FA019-07A4-4451-AB0C-9B80F075D37D Q30426724-DE848A8B-E368-4C32-9E9B-01BCC6BF57BA Q30542081-6BAA1444-7DAF-4503-9029-02B21B2C201A Q33588294-21085196-5CCF-4855-B1F6-CFED8BE911CB Q33638116-4D6059E6-B9A8-46F0-B030-BFA08546635B Q33805484-28876FDA-7481-411F-AC71-8484CA6F3836 Q34623633-A2082D45-AD5D-4B23-BDBB-100FCCE90721 Q34815207-733791DF-8131-4DD1-9305-CF55F7C7D649 Q35114090-8AC8C8DE-F4DB-4E24-A680-423BB12EC6E0 Q35811181-501869BD-85C7-4BEC-9ECB-FBA92CACAD0C Q36037100-82D75927-F962-4219-BAE4-8B9A1D21567E Q36559617-9F9E95CD-E0A6-472C-B69F-24791074120B Q37037132-D83BB1C2-7856-4A66-915A-9E97D577A2DC Q37284303-FF715BC5-5801-4799-9228-5A79A7EC227B Q37429161-A64C446F-8103-4409-8657-B52CEDD35207 Q37575528-603FE06F-5BD6-4568-9D0D-661A7569D37F Q37714906-005A96B2-AF59-4B72-A2C6-A02FD6E715F1 Q37883145-F6D478FA-AD0D-41C2-80CB-C0654DD9B0A0 Q38035066-AFD9360F-9468-44D4-89B7-565994FFA100 Q38070698-ACE87EFF-2AAA-4B02-86C6-94596C87CAEA Q38456018-491AC45B-84F2-439D-9A6E-02D89B44416B Q38461565-B72DA3B5-AFDC-4531-BA80-9AB326745EDF Q39373950-37DBABCC-8A9F-4904-A5DC-66C6562C0E26 Q39453835-157492A7-5B85-4DEC-AD2F-B5CC92351EC6 Q39480039-44A98793-7AF1-4D60-ADA9-3877B429DC40 Q39613243-BF9305C1-A94F-412B-B053-DF1F7BBD08E0 Q40572125-7AA7D8E2-1641-4083-86A3-1CCEC026E8A0 Q41404126-D8123686-A321-44AC-B750-703785B1171F Q41890894-AD7374ED-3AF7-4E23-9F2F-1A8873FEC665 Q42425945-BA0A0556-9E8A-49AA-8583-BB49A763495F Q45975426-8E3941AB-C5E0-43F9-9623-187DA95261E2 Q48161996-D47C07E9-1389-4E39-8D14-BAEEE261C9A6 Q48250296-5EECA3EB-6CDA-4436-9EC4-D4628D430C32 Q48910170-679E081C-5D23-426F-B5EF-60235F52E20D Q49317056-7B38A28A-3D21-44F3-AE4D-2B7814DAF479 Q52096930-B9E4AAEB-6204-4AFF-AC91-8BA9F952896B Q55004492-98C308A8-49BA-4F4D-A04E-9D6B4A6AAE9D Q55463196-448FA167-8E76-473D-AFBF-77AD36C92B0D

P2860

Survey of treatment recommendations for anaplastic oligodendroglioma

http://www.wikidata.org/entity/Q30441461

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Survey of treatment recommendations for anaplastic oligodendroglioma

@ast

Survey of treatment recommendations for anaplastic oligodendroglioma

@en

type

label

Survey of treatment recommendations for anaplastic oligodendroglioma

@ast

Survey of treatment recommendations for anaplastic oligodendroglioma

@en

prefLabel

Survey of treatment recommendations for anaplastic oligodendroglioma

@ast

Survey of treatment recommendations for anaplastic oligodendroglioma

@en

P1433

Q30441461-496EE7DB-B4B4-47F9-AAAE-561DB88AB9D1

P1476

Q30441461-4F0D8881-082E-4F7C-9B7A-26FDE4846EDD

P2093

Q30441461-2A98570C-CE78-4F04-A2A8-E0D2C40E52DE

Q30441461-409DF7E8-EA06-463F-BF84-7BB2F7B3331F

Q30441461-424E5A2A-59E4-40D7-B883-6774F6324828

Q30441461-51FF8567-D64D-41AE-A925-44406C034214

Q30441461-53AAA8E7-155A-4C89-983D-23B7FD842705

Q30441461-67F98DAC-0715-4E63-AE85-97FCE1855A54

Q30441461-6FC693F7-0492-4633-A25F-F555C096B8AB

Q30441461-7273E107-069B-43D7-8C62-DF8EC8AA7F9D

Q30441461-99570E19-423C-4F77-9B60-3C2B0ED9CE77

Q30441461-DEFDED94-F700-49D7-8D01-C0FE3BC33897

P2860

Q30441461-09E82855-DDD8-48CB-B5AA-0F29F476BBA3

Q30441461-0AA62C11-74E8-4574-BB23-B8CF6699246F

Q30441461-1F315657-5EDE-40CA-8F62-FD255ABD5F48

Q30441461-249AA7B3-F195-4F28-960B-BB4018118AFC

Q30441461-2EAF5597-A9E1-471E-BD61-E4C00ABDA777

Q30441461-4E2F9846-870A-424B-845D-A912B8BA64F8

Q30441461-6974E319-C02D-4A89-A448-0ED29E6FE04C

Q30441461-6E702EA9-8A63-4EDD-BF38-52A3858CC38B

Q30441461-7A08026D-EDED-4193-8551-9D61BBD8C7A1

Q30441461-8517D6E6-F8B8-407E-ADA7-9A4A7205F758

P304

Q30441461-A503F28C-FB24-473D-95B1-36EFC5E68DDE

P31

Q30441461-0CC54EC4-653B-40E6-B962-B8385952178D

P356

Q30441461-ABE91B0F-16CE-4B2B-8547-3B53100C0B62

P433

Q30441461-CCA7E842-61F0-4884-AEC6-57DF31B8E9EF

P478

Q30441461-4A7415CB-0F50-4488-AB23-539991745CB6

P50

Q30441461-3E6BBF0E-7973-415F-BC74-DFCD104E18A2

P577

Q30441461-D159C01B-37CB-4A32-9131-18884BB8048A

P5875

Q30441461-8EEE3A6F-0E4C-43C2-9F6D-6CFF4A6005A4

P698

Q30441461-022A8830-A46A-4EA5-BD04-4B9933F27418

P921

Q30441461-0F69A673-B9E1-4460-B4C0-4FD000B773B1

P932

Q30441461-EEFADAAB-B68E-4BBB-B93C-90367DA8E20C

P356

15228517-2007-002

P1433

P1476

Survey of treatment recommendations for anaplastic oligodendroglioma

@en

P2093

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

David N Louis

http://www.w3.org/2001/XMLSchema#string

David R MacDonald

http://www.w3.org/2001/XMLSchema#string

J Gregory Cairncross

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Raizer

http://www.w3.org/2001/XMLSchema#string

Jonathan Finlay

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

Nina Paleologos

http://www.w3.org/2001/XMLSchema#string

Oligodendroglioma Study Group

http://www.w3.org/2001/XMLSchema#string

Warren Mason

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.

Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading.

P304

314-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1215/15228517-2007-002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Lisa M DeAngelis

P577

2007-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6393604

http://www.w3.org/2001/XMLSchema#string

P698

17435180

http://www.w3.org/2001/XMLSchema#string

P921

oligodendroglioma

P932

1907408

http://www.w3.org/2001/XMLSchema#string